Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris

Archives of Dermatology

Volumn 144, Issue 1, 2008, Pages 25-32

  Werth, Victoria P ^a,b,k   Fivenson, David ^c,h   Pandya, Amit G ^d   Chen, Diana ^e,i   Rico, M Joyce ^f,j   Albrecht, Joerg ^a,k   Jacobus, David ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^f NEW YORK UNIVERSITY   (United States)

^g Jacobus Pharmaceutical Co Inc   (United States)

^h Connetics Corp ^*

ⁱ ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^j Jr Hospital of Cook County   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; GLUCOCORTICOID; PLACEBO; PREDNISONE; STEROID;

ADULT; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMOLYSIS; HUMAN; IMMUNOFLUORESCENCE; MAINTENANCE THERAPY; MALE; METHEMOGLOBINEMIA; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CROSS-OVER STUDIES; DAPSONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PEMPHIGUS; PREDNISONE; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38549139173     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.1.25     Document Type: Article

References (23)

1. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol. 1984;120(7):941-951.
2. Enk AH, Knop J, Enk A, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;135(1):54-56.
3. Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149(1):138-145.
4. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139(6):739-742.
5. Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol. 1978;114(6):889-894.
6. Piamphongsant T. Treatment of pemphigus with corticosteroids and cyclophosphamide. J Dermatol. 1979;6(6):359-363.
7. Chrysomallis F, Ioannides D, Teknetzis A, Panagiotidou D, Minas A. Treatment of oral pemphigus vulgaris. Int J Dermatol. 1994;33(11):803-807.
8. Benoit Corven C, Carvalho P, Prost C, et al. Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme). Ann Dermatol Venereol. 2003;130(1, pt 1):13-15.
9. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 1987;16(3, pt 1):527-533.
10. Akhtar SJ, Hasan MU. Treatment of pemphigus: a local experience. J Pak Med Assoc. 1998;48(10):300-304.
11. Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol. 2003;49(6):1059- 1062.
12. DeHoratius DM, Sperber BR, Werth VP. Glucocorticoids in the treatment of bullous diseases. Dermatol Ther. 2002;15(4):298-310.
13. Winkelmann RK, Roth HL. Dermatitis herpetiformis with acantholysis or pemphigus with response to sulfonamides. Arch Dermatol. 1960;82(3):385-390.
14. Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica. 1978;156(2):120-123.
15. Jablonska S, Chorzelski T. When and how to use sulfones in bullous diseases. Int J Dermatol. 1981;20(2):103-105.
16. Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol. 1976;94(6):681-686.
17. Barranco VP. Dapsone: other indications. Int J Dermatol. 1982;21(9):513-514.
18. Seah PP, Fry L, Cairns RJ, Feiwel M. Pemphigus controlled by sulphapyridine. Br J Dermatol. 1973;89(1):77-81.
19. Pearson RW, O'Donoghue M, Kaplan SJ. Pemphigus vegetans: its relationship to eosinophilic spongiosis and favorable response to dapsone. Arch Dermatol. 1980;116(1):65-68.
20. Piamphongsant T, Ophaswongse S. Treatment of pemphigus. Int J Dermatol. 1991;30(2):139-146.
21. Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2005;141(6):699-702.
22. Mentink LF, Mackenzie MW, Toth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial [published correction for error in dosage appears in Arch Dermatol. 2006;142(8):1014]. Arch Dermatol. 2006;142(5):570-576.
23. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142(11):1447-1454.